https://doi.org/10.1177/1179550618821930. PMID: 30670922. PMCID: PMC6328955.

2. Niederman M.S., Torres A. Respiratory infections. Eur Respir Rev. 2022; 31(166): 220150.

https://doi.org/10.1183/16000617.0150-2022. PMID: 36261160. PMCID: PMC9724828.

3. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011; 17: Suppl. 6: E1–E59.

https://doi.org/10.1111/j.1469-0691.2011.03672.x. PMID: 21951385. PMCID: PMC7128977.

4. GBD 2016. Lower Respiratory Infections Collaborators. Estimates of the global, regional and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11): 1191–1210.

https://doi.org/10.1016/s1473-3099(18)30310-4. PMID: 30243584. PMCID: PMC6202443.

5. Sliedrecht A., den Elzen W.P., Verheij T.J. et al. Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study. Thorax. 2008; 63(9): 817–22.

https://doi.org/10.1136/thx.2007.093013. PMID: 18388206.

6. Reynolds D., Burnham J.P., Vazquez Guillamet C. et al. The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: Another pandemic. Eur Respir Rev. 2022; 31(166): 220068.

https://doi.org/10.1183/16000617.0068-2022. PMID: 36261159. PMCID: PMC9724833.

7. Naqvi K.F., Mazzone S.B., Shiloh M.U. Infectious and inflammatory pathways to cough. Annu Rev Physiol. 2023; 85: 71–91.

https://doi.org/10.1146/annurev-physiol-031422-092315. PMID: 36170660. PMCID: PMC9918720.

8. McGovern A.E., Short K.R., Moe A.A.K., Mazzone S.B. Translational review: Neuroimmune mechanisms in cough and emerging therapeutic targets. J Allergy Clin Immunol. 2018; 142(5): 1392–1402.

https://doi.org/10.1016/j.jaci.2018.09.004. PMID: 30409248.

9. Jones R.M., Brosseau L.M. Aerosol transmission of infectious disease. J Occup Environ Med. 2015; 57(5): 501–8.

https://doi.org/10.1097/jom.0000000000000448. PMID: 25816216.

10. Abdullah H., Heaney L.G., Cosby S.L., McGarvey L.P. Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line: Implications for respiratory virus-induced cough reflex sensitivity. Thorax. 2014; 69(1): 46–54.

https://doi.org/10.1136/thoraxjnl-2013-203894. PMID: 24002057.

11. Mazzone S.B., Undem B.J. Vagal afferent innervation of the airways in health and disease. Physiol Rev. 2016; 96(3): 975–1024.

https://doi.org/10.1152/physrev.00039.2015. PMID: 27279650. PMCID: PMC4982036.

12. Lai K., Lin L., Liu B. et al. Eosinophilic airway inflammation is common in subacute cough following acute upper respiratory tract infection. Respirology. 2016; 21(4): 683–88.

https://doi.org/10.1111/resp.12748. PMID: 26969485.

13. Прохорович Е.А., Силина Е.Г. Лекарственные препараты для лечения кашля и заболеваний, сопровождающихся выделением мокроты. РМЖ. Медицинское обозрение. 2019; 3(9-1): 25–28. (Prohorovich E.A., Silina E.G. Medicines for the treatment of cough and diseases accompanied by sputum production. Russkiy meditsisnkiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2019; 3(9-1): 25–28 (In Russ.)). EDN: XMIKRM.

14. Казанцев В.А. Мукоактивная терапия при лечении больных с инфекциями нижних дыхательных путей. Медицинский совет. 2015; (16): 83–89. (Kazantsev V.A. Mucoactive therapy in the treatment of patients with lower respiratory tract infections. Meditsinskiy sovet = Medical Council. 2015; (16): 83–89 (In Russ.)). EDN: UNTMVT.

15. Бабак С.Л., Горбунова М.В., Малявин А.Г. Муцины и карбоцистеин: защита дыхательных путей. Терапия. 2021; 7(10): 160–168. (Babak S.L., Gorbunova M.V., Malyavin A.G. Mucins and carbocisteine: Respiratory protection. Terapiya = Therapy. 2021; 7(10): 160–168 (In Russ.)).

https://doi.org/10.18565/therapy.2021.10.160-168. EDN: JTAWPA.

16. Ходзицкая В.К., Ходзицкая С.В. Нарушение и коррекция мукоцилиарного клиренса при заболеваниях дыхательных путей и ЛОР-органов. Болезни и антибиотики. 2010. Доступ: http://antibiotic.mif-ua.com/archive/issue-14554/article-14576/ (дата обращения – 22.08.2024). (Khodzitskaya V.K., Khodzitskaya S.V. Disturbance and correction of mucociliary clearance in diseases of the respiratory tract and ENT organs. Bolezni i antibiotiki = Diseases and Antibiotics. 2010. URL: http://antibiotic.mif-ua.com/archive/issue-14554/article-14576/ (date of access – 22.08.2024) (In Russ.)).

17. Hill D.B., Button B., Rubinstein M., Boucher R.C. Physiology and pathophysiology of human airway mucus. Physiol Rev. 2022; 102(4): 1757–1836.

https://doi.org/10.1152/physrev.00004.2021. PMID: 35001665. PMCID: PMC9665957.

18. Ntyonga-Pono M.-P. COVID-19 infection and oxidative stress: An under-explored approach for prevention and treatment? Pan Afr Med J. 2020; 35(Suppl 2): 12.

https://doi.org/10.11604/pamj.2020.35.2.22877. PMID: 32528623. PMCID: PMC7266475.

19. Bianco A., Conte S., Mariniello D.F. et al. Mucolytic and antioxidant properties of carbocysteine as a strategy in COVID-19 therapy. Life (Basel). 2022; 12(11): 1824.

https://doi.org/10.3390/life12111824. PMID: 36362979. PMCID: PMC9692377.

20. Государственный реестр лекарственных средств Минздрава России. Инструкция по применению лекарственного препарата для медицинского применения Касцебене. РУ: ЛП-№(000670)-(РГ-RU) от 06.04.2022. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=40688d8d-0a2d-45f4-8fe8-10dc42c334ff (дата обращения – 21.08.2024). (State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for use of the medicinal product for medical use Kascebene. Registration certificate: ЛП-№(000670)-(РГ-RU) dated 04/06/2022. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=40688d8d-0a2d-45f4-8fe8-10dc42c334ff (date of access – 21.08.2024) (In Russ.)).

21. Hooper C., Calvert J. The role for S-carboxymethylcysteine (Carbocysteine) in the management of chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm. Dis. 2008; 3(4): 659–69. PMID: 19281081. PMCID: PMC2650606.

22. Pace E., Cerveri I., Lacedonia D. et al. Clinical efficacy of carbocysteine in COPD: Beyond the mucolytic action. Pharmaceutics. 2022; 14(6): 1261.

https://doi.org/10.3390/pharmaceutics14061261. PMID: 35745833. PMCID: PMC9227620.

23. Braga P.C., Scaglione F., Scarpazza G. et al. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res. 1985; 5(5): 331–40. PMID: 4066083.

24. Kahraman M.E., Yüksel F., Özbuğday Y. The relationship between Covid-19 and mucociliary clearance. Acta Otolaryngol. 2021; 141(11): 989–93.

https://doi.org/10.1080/00016489.2021.1991592. PMID: 34694199.

25. Wang W., Guan W.-J., Huang R.-Q. et al. Carbocysteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways. Acta Pharmacol Sin. 2016; 37(5): 629–36.

https://doi.org/10.1038/aps.2015.150. PMID: 26997568. PMCID: PMC4857541.

26. Laforge M., Elbim C., Frere C. et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020; 20(9): 515–16.

https://doi.org/10.1038/s41577-020-0407-1. PMID: 32728221. PMCID: PMC738842.

27. Wu J. Tackle the free radicals damage in COVID-19. Nitric Oxide. 2020; 102: 39–41.

https://doi.org/10.1016/j.niox.2020.06.002. PMID: 32562746. PMCID: PMC7837363.

28. Bakadia B.M., Boni B.O.O., Ahmed A.A.Q., Yang G. The impact of oxidative stress damage induced by the environmental stressors on COVID-19. Life Sci. 2021; 264: 118653.

https://doi.org/10.1016/j.lfs.2020.118653. PMID: 33115606. PMCID: PMC7586125.

29. Horby P., Lim W.S., Emberson J.R. et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8): 693–704.

https://doi.org/10.1056/nejmoa2021436. PMID: 32678530. PMCID: PMC7383595.

30. Лещенко И.В. Острый бронхит. М.: ГЭОТАР-Медиа. 2019; 96 с. (Leshchenko I.V. Acute bronchitis. Moscow: GЕOTAR-Media. 2019; 96 pp. (In Russ.)). ISBN: 978-5-9704-4827-4.

31. Bonser L.R., Erle D.J. Airway mucus and asthma: The role of MUC5AC and MUC5B. J Clin Med. 2017; 6(12): 112.

https://doi.org/10.3390/jcm6120112. PMID: 29186064. PMCID: PMC5742801.

32. Linden D., Guo-Parke H., Coyle P.V. et al. Respiratory viral infection: A potential “missing link” in the pathogenesis of COPD. Eur Respir Rev. 2019; 28(151): 180063.

https://doi.org/10.1183/16000617.0063-2018. PMID: 30872396. PMCID: PMC9488189.

33. Vogelmeier C.F., Román Rodríguez M., Singh D. et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020; 166: 105938.

https://doi.org/10.1016/j.rmed.2020.105938. PMID: 32250871.

34. Zeng Z., Yang D., Huang X., Xiao Z. Effects of carbocysteine on patients with COPD: A systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2277–83.

https://doi.org/10.2147/COPD.S140603. PMID: 28814855. PMCID: PMC5546781.

35. Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomised placebo-controlled study. Lancet. 2008; 371(9629): 2013–18.

https://doi.org/10.1016/S0140-6736(08)60869-7. PMID: 18555912.